Stocks Health care DYN
NASDAQ · Health careDyne Therapeutics, Inc. (DYN)
It posted a net loss of $604.9M. In fiscal 2025 capital spending exceeded operating cash flow by $405.1M. At September 30, 2026 it held $913.2M in cash against $200M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about Dyne Therapeutics, Inc.
- Net worth
- Dyne Therapeutics, Inc. has a market value (market cap) of $3.3B at the latest share price, and shareholders' equity of $930.9M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $403.2M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Dyne Therapeutics, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Dyne Therapeutics, Inc. does
Dyne Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker DYN.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$446.2M | -$3.47 | -$405.1M |
| 2024 | n/a | -$317.4M | -$3.37 | -$294.7M |
| 2023 | n/a | -$235.9M | -$3.95 | -$188.9M |
| 2022 | n/a | -$168.1M | -$3.23 | -$156.7M |
| 2021 | n/a | -$149.3M | -$2.93 | -$123.2M |
| 2020 | n/a | -$59.4M | -$4.13 | -$47.7M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Dyne Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026
- November 5, 2026
- September 29, 2026
- August 13, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026Passive stake changed SCHEDULE 13G/A
- August 6, 2026Passive stake changed SCHEDULE 13G/A
- July 29, 2026
- July 29, 2026
- July 28, 2026Passive stake changed SCHEDULE 13G/A
- July 22, 2026
Insider trades
What the people running Dyne Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $40K and sold $65.7M worth of shares in the last 90 days. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 20, 2026 | Kerr DouglasHead of R&D and CMO | Received as pay | 8,000 | - |
| October 2, 2026 | Posner Brian SDirector | Bought | 2,500 | $40K |
| September 8, 2026 | Cox JohnCEO & President, Director | Soldpre-planned (10b5-1) | 5,658 | $106.8K |
| September 8, 2026 | Kerr DouglasChief Medical Officer | Soldpre-planned (10b5-1) | 1,290 | $24.4K |
| September 8, 2026 | Friedl-Naderer JohannaChief Commercial Officer | Soldpre-planned (10b5-1) | 185 | $3.5K |
| September 4, 2026 | Kerr DouglasChief Medical Officer | Soldpre-planned (10b5-1) | 3,745 | $91.2K |
| September 4, 2026 | Friedl-Naderer JohannaChief Commercial Officer | Soldpre-planned (10b5-1) | 900 | $21.9K |
| August 14, 2026 | Rhodes Jason PDirector | Soldpre-planned (10b5-1), indirect | 1,359,674 | $34M |
Who owns DYN
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| T. Rowe Price Investment Management, Inc.13G, passive | 18.7% | May 15, 2026 |
| JANUS HENDERSON GROUP Ltd.13G, passive | 7.3% | August 13, 2026 |
| Fmr LLC13G, passive with 1 related filers | 6.8% | August 6, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 246 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 12,404,330 | +704,460 |
| Jupiter Topco LLC | 11,997,738 | new |
| Fmr LLC | 11,207,000 | +2,298,020 |
| State Street Corp | 7,458,263 | +804,517 |
| Orbis Allan Gray Ltd | 7,006,542 | +244,311 |
| Atlas Venture Life Science Advisors, LLC | 6,800,099 | -2,330,366 |
| Vanguard Capital Management LLC | 6,310,969 | -94,100 |
| TCG Crossover Management, LLC | 4,615,144 | 0 |
| Vanguard Portfolio Management LLC | 4,048,428 | -113,613 |
| Fcpm III Services B.V. | 3,848,256 | -796,130 |
| Geode Capital Management, LLC | 3,743,427 | +239,313 |
| Vestal Point Capital, LP | 3,375,000 | -625,000 |
| Orbimed Advisors LLC | 3,235,684 | +317,800 |
| Frazier Life Sciences Management, L.P. | 3,153,082 | 0 |
| Armistice Capital, LLC | 3,087,226 | -87,884 |
| Jpmorgan Chase & Co | 3,151,656 | -101,817 |
| Perceptive Advisors LLC | 2,689,235 | -1,979,604 |
| Logos Global Management LP | 2,550,000 | +1,150,000 |
| Bank of America Corp | 2,233,398 | +790,085 |
| Venrock Adviser, LLC | 2,173,913 | 0 |
Insiders
7 insiders reported holding 4,843,476 shares in total, about $86.2M at the last price.
| Holder | Shares |
|---|---|
| Kersten DirkDirector | 3,586,7963,586,796 held indirectly |
| Rhodes Jason PDirector | 428,946428,946 held indirectly |
| Cox JohnCEO & President, Director | 357,507 |
| Kerr DouglasHead of R&D and CMO | 170,564 |
| Friedl-Naderer JohannaChief Commercial Officer | 152,897 |
| Lucera ErickChief Financial Officer | 119,766 |
| Posner Brian SDirector | 27,000 |
Questions about DYN
What does Dyne Therapeutics, Inc. do?
Dyne Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as DYN. Its shares trade on NASDAQ under the ticker DYN.
What is Dyne Therapeutics, Inc.'s net worth?
Dyne Therapeutics, Inc. has a market value (market cap) of $3.3B at the latest share price, and shareholders' equity of $930.9M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Dyne Therapeutics, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $604.9M.
When did Dyne Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026.
When is Dyne Therapeutics, Inc.'s next earnings report?
Dyne Therapeutics, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare DYN with
Follow DYN
Get an email when Dyne Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Dyne Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.